Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Non-Tech : NIFTY NINE IN NINETY NINE PLUS ONE -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (122)	1/13/1999 3:08:00 PM
From: Mike McFarland	Respond to of 613

Does Aurora have anything starting out in trials, or are they more of a genomics company...ah, yes I see they are a functional genomics company. I did a quick query and did not see any clinical drug trials...it has been on my watch list, but I have never begun any DD --and I see it is in the wrong watch list...will move it into the gene group. I see it is at roughly twice book, which is actually a bit more than what seems to trigger my into looking at the stock. Could you give a little primer on it?

To: Steve Lokness who wrote (122)	1/13/1999 5:48:00 PM
From: Arthur Radley	Read Replies (1) \| Respond to of 613

Adding to what Mike said, give us a little background on ABSC. Especially any info that will support their breaking even this year. I spoke earlier this week with an old friend from California(he is retired from having his own seat on the Pacific Exchange) and he warned me about a violent downdraft that he expected in the market by Friday's expiration of options. Even though we got a good "shaking" today and a nice recovery, I still think my friend's words of caution might be further felt before the week is out.